CNM-ZnAg
/ Clene
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
February 08, 2023
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
(clinicaltrials.gov)
- P2 | N=296 | Completed | Sponsor: Clene Nanomedicine | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease
July 19, 2022
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
(clinicaltrials.gov)
- P2 | N=276 | Active, not recruiting | Sponsor: Clene Nanomedicine | Trial completion date: May 2022 ➔ Aug 2022
Trial completion date • Infectious Disease • Novel Coronavirus Disease
March 29, 2022
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
(clinicaltrials.gov)
- P2 | N=276 | Active, not recruiting | Sponsor: Clene Nanomedicine | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Aug 2021 ➔ May 2022 | Trial primary completion date: Jul 2021 ➔ May 2022
Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
February 16, 2021
Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19
(GlobeNewswire)
- "...Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, received official ANVISA approval in Brazil to commence its multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of CNM-ZnAg liquid solution in a Phase 2 clinical study...Participants in the Phase 2 study must have presented with two or more symptoms of acute COVID-19 infection within 96 hours prior to baseline visit, self-reported as moderate or severe....Enrollment in the trial is expected to be completed in mid-2021, with results now anticipated in the second half of 2021."
New P2 trial • P2 data • Trial completion date • Infectious Disease • Novel Coronavirus Disease
October 30, 2020
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
(clinicaltrials.gov)
- P2; N=238; Not yet recruiting; Sponsor: Clene Nanomedicine
Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease
1 to 5
Of
5
Go to page
1